Form 8-K - Current report:
SEC Accession No. 0001104659-25-110548
Filing Date
2025-11-13
Accepted
2025-11-12 17:49:26
Documents
13
Period of Report
2025-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K anvs-20251112x8k.htm   iXBRL 8-K 36431
2 EX-99 anvs-20251112xex99.htm EX-99 149379
  Complete submission text file 0001104659-25-110548.txt   310787

Data Files

Seq Description Document Type Size
3 EX-101.SCH anvs-20251112.xsd EX-101.SCH 2677
4 EX-101.LAB anvs-20251112_lab.xml EX-101.LAB 16579
5 EX-101.PRE anvs-20251112_pre.xml EX-101.PRE 10716
15 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20251112x8k_htm.xml XML 5080
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 251474592
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)